ABL1 and acute lymphoblastic leukemia: In contrast, 17.21% mutations (5/29) in BCR::ABL1‐positive ALL subjects emerging after exposure to 1stG TKI were resistant, and 13.51% mutations (5/37) emerged after exposure to 2nd G TKI.